Cargando…

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

BACKGROUND: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ely, E Wesley, Ramanan, Athimalaipet V, Kartman, Cynthia E, de Bono, Stephanie, Liao, Ran, Piruzeli, Maria Lucia B, Goldman, Jason D, Saraiva, José Francisco Kerr, Chakladar, Sujatro, Marconi, Vincent C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813065/ https://www.ncbi.nlm.nih.gov/pubmed/35123660 http://dx.doi.org/10.1016/S2213-2600(22)00006-6

Ejemplares similares

LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial
por: Ely, E Wesley, et al.
Publicado: (2021)

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
por: Marconi, Vincent C, et al.
Publicado: (2021)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2021)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

A quantile-based method for association mapping of quantitative phenotypes: an application to rheumatoid arthritis phenotypes
por: Ghosh, Saurabh, et al.
Publicado: (2009)

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
por: Wolfe, Cameron R, et al.
Publicado: (2022)

Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA
Publicado: (2021)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
por: KIM, Han Seul, et al.
Publicado: (2023)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
por: Pérez-Alba, Eduardo, et al.
Publicado: (2021)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Advancing Transition in Resource-Constrained Settings
por: Sinnappurajar, Praisoody, et al.
Publicado: (2022)

Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children
por: Chew, Christine, et al.
Publicado: (2023)

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
por: Titanji, Boghuma K, et al.
Publicado: (2020)

Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs
por: Crosby, Laura, et al.
Publicado: (2021)

Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?
por: Ramanan, Athimalaipet V., et al.
Publicado: (2022)

The association of delirium severity with patient and health system outcomes in hospitalised patients: a systematic review
por: Rosgen, Brianna K, et al.
Publicado: (2020)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
por: Stebbing, Justin, et al.
Publicado: (2020)

15. Eosinophilic pneumonitis secondary to baricitinib
por: Yein, Khin, et al.
Publicado: (2019)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

Baricitinib: Two Birds with One Stone
por: Saj, Fen, et al.
Publicado: (2022)

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
por: Fautrel, Bruno, et al.
Publicado: (2019)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Physiologic responses to exercise in survivors of critical illness: an exploratory pilot study
por: Mart, Matthew F., et al.
Publicado: (2022)

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
por: Dörner, Thomas, et al.
Publicado: (2022)

Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al
por: Titanji, Boghuma K, et al.
Publicado: (2020)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
por: Deprez, Valentine, et al.
Publicado: (2020)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rpdmlju09ug1muh8maofqa605d